Menu
Search
|

Menu

Close
X

Oxford Immunotec Global PLC OXFD.OQ (NASDAQ Stock Exchange Global Market)

12.68 USD
-0.14 (-1.09%)
As of Jul 20
chart
Previous Close 12.82
Open 12.82
Volume 17,251
3m Avg Volume 45,672
Today’s High 12.92
Today’s Low 12.66
52 Week High 19.50
52 Week Low 10.26
Shares Outstanding (mil) 25.88
Market Capitalization (mil) 331.80
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
21
FY17
103
FY16
86
FY15
63
EPS (USD)
FY18
-0.401
FY17
-0.610
FY16
-1.000
FY15
-1.127
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.34
Price to Sales (TTM)
vs sector
3.22
8.11
Price to Book (MRQ)
vs sector
4.12
4.23
Price to Cash Flow (TTM)
vs sector
--
22.22
Total Debt to Equity (MRQ)
vs sector
37.82
17.18
LT Debt to Equity (MRQ)
vs sector
37.71
13.08
Return on Investment (TTM)
vs sector
-13.06
13.18
Return on Equity (TTM)
vs sector
-18.83
15.09

EXECUTIVE LEADERSHIP

Richard Sandberg
Independent Chairman of the Board, Since 2008
Salary: --
Bonus: --
Peter Wrighton-Smith
Chief Executive Officer, Director, Since 2002
Salary: $404,817.00
Bonus: --
Richard Altieri
Chief Financial Officer, Since 2012
Salary: $315,000.00
Bonus: --
Stefan Linn
Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Elizabeth Keiley
Senior Vice President, General Counsel, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

94C Innovation Drive, Milton Par
ABINGDON     OX14 4RZ

Phone: +441235.442780

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company's product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Its T-SPOT.TB test is used to test for tuberculosis (TB), infection and leverages its T-SPOT technology platform, which allows it to measure the response of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease. Its T-SPOT. CMV and T-SPOT. PRT tests are part of its product line focused on the transplantation market.

SPONSORED STORIES